CVS Health has topped second-quarter earnings expectations and lifted its full-year profit forecast, citing improved performance in its insurance business and stronger prescription drug revenues.
The pharmacy and healthcare giant also unveiled a new collaboration with Eli Lilly that will make the weight-loss drug Zepbound and the diabetes medication Foundayo accessible to eligible patients directly through the CVS Health app.
The upgraded guidance underscores a turnaround for CVS’s Aetna insurance arm, which had weighed on results in prior quarters as medical costs surged. The unit’s continued improvement has helped restore investor confidence in the company’s diversified healthcare model.
Stronger drug revenues also played a central role in the quarter, reflecting robust demand across the company’s pharmacy operations. The rising popularity of GLP-1 medications, used for both diabetes and weight management, has become a significant driver of prescription volumes across the U.S. healthcare sector.
The partnership with Eli Lilly deepens ties between CVS and one of the leading manufacturers of GLP-1 therapies. The maker of Zepbound has seen surging demand, and CVS’s digital platform is expected to streamline access for patients who qualify for treatment.
Eli Lilly’s weight-loss and diabetes franchise has expanded rapidly in recent years, with the company having lifted its own outlook on the back of soaring GLP-1 sales. Integrating those drugs into the CVS Health app positions the retailer to capture a share of that growing market through its consumer-facing technology.
The move comes as pharmacy benefit managers and insurers race to secure favorable positions in the fast-growing weight-loss drug space, balancing patient demand against the high costs of the medications.
CVS operates one of the largest integrated healthcare networks in the United States, spanning retail pharmacies, insurance through Aetna, and pharmacy benefit management via Caremark. The company has spent recent years working to stabilize margins across those segments.
With the raised forecast, CVS signals confidence in sustaining momentum through the remainder of the year. The company is expected to provide further detail on the Eli Lilly collaboration and its insurance recovery in coming quarters.